{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.526.3.1487","meta":{"versionId":"18","lastUpdated":"2017-09-26T01:00:05.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"PCPI Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2017-09-26"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1487","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.526.3.1487"}],"version":"20170926","name":"TamoxifenOrAromataseInhibitorTherapyIngredient","title":"Tamoxifen or Aromatase Inhibitor Therapy Ingredient","status":"active","experimental":false,"date":"2017-09-26T01:00:05-04:00","publisher":"PCPI Steward","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development)","compose":{"include":[{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1913"]}]},"expansion":{"identifier":"urn:uuid:3ad2dbb4-c052-44c0-9553-d8a3318a1390","timestamp":"2023-12-11T02:57:23-05:00","total":4,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"10324","display":"tamoxifen"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"258494","display":"exemestane"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"72965","display":"letrozole"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"84857","display":"anastrozole"}]}}